Characteristics | ESBL | AmpC | MDR | |||
---|---|---|---|---|---|---|
cOR (95Â % CI) | aOR (95Â % CI) | cOR (95Â % CI) | aOR (95Â % CI) | cOR (95Â % CI) | aOR (95Â % CI) | |
Age | ||||||
 0–14 |  |  |  |  | 1.0 | 1.0 |
 15–44 |  |  |  |  | 1.65 (1.22, 2.23)a | 6.49 (0.91, 46.16) |
 45+ |  |  |  |  | 1.38 (0.90, 2.12) | 1.89 (0.21, 16.75) |
Sex | ||||||
 Female |  |  | 1.0 | 1.0 |  |  |
 Male |  |  | 1.52 (0.88, 2.63) | 1.51 (0.76, 2.97) |  |  |
HC level | ||||||
 NR | 1.0 | 1.0 |  |  | 1.0 | 1.0 |
 GH | 1.65 (0.35, 7.8) | 0.89 (0.15, 5.28) |  |  | 0.32 (0.20, 0.52)a | 0.18 (0.001, 27.32) |
 HCIV | 0.53 (0.07, 3.98) | 0.31 (0.03, 2.88) |  |  | 0.27 (0.16, 0.46)a | 1.96 (0.01, 491.00) |
 HCIII | – | – |  |  | 0.21 (0.13, 0.33)a | 2.59 (0.02, 331.66) |
District | ||||||
 Kampala |  |  |  |  | 1.0 | 1.0 |
 Kayunga |  |  |  |  | 0.17 (0.12, 0.24)a | 0.02 (0.00, 3.54) |
 Mpigi |  |  |  |  | 0.20 (0.14, 0.28)a | 0.36 (0.003, 38.44) |
HSD | ||||||
 Cases >100 | 1.0 | 1.0 |  |  | 1.0 | 1.0 |
 Cases <100 | 6.77 (0.81, 56.94) | 6.71 (0.46, 97.96) |  |  | 1.75 (1.33, 2.29)a | 0.13 (0.001, 12.37) |
Reason for visit | ||||||
 ISS |  |  | 1.0 | 1.0 |  |  |
 Infection |  |  | 1.38 (0.44, 4.35) | 1.72 (0.47, 6.35) |  |  |
 General |  |  | 3.42 (1.05, 11.12)a | 4.38 (1.14, 16.84)a |  |  |
History of admission | ||||||
 Yes |  |  | 2.76 (1.12, 6.84)a | 2.92 (0.95, 9.02) |  |  |
History of medical procedures | ||||||
 Contact |  |  |  |  | 1.0 | 1.0 |
 Inoculation |  |  | 4.11 (0.45, 37.69) | 50.76 (1.80, 1432.98)a | ||
 Surgery |  |  | 0.83 (0.06, 11.42) | 2.48 (0.06, 99.30) | ||
 Antibiotic use | ||||||
  Yes | 4.47 (1.15, 17.44)a | 4.57 (0.90, 23.20) |  |  | 0.79 (0.58, 1.07)a |  |
 Use of gentamicin | ||||||
  Yes |  |  | 0.27 (0.05, 1.32) | 0.17 (0.03, 0.95)a |  |  |
 Use of ciprofloxacin | ||||||
  Yes |  |  |  |  | 1.52 (0.96, 2.40)a | 5.71 (0.69, 47.01) |
 Use of septrin | ||||||
  Yes | 4.33 (0.84, 22.47) | 4.70 (0.33, 66.82) |  |  | 0.53 (0.40, 0.71)a | 1.92 (0.45, 8.23) |